Indeed, the expression of IDO1 in tumor cells was an important driver in the development of the concept that tryptophan depletion in cancer could inhibit anti-cancer immune function and ergo, IDO1 inhibitors would theoretically promote immune defense (especially T cell responses) against cancer. This evidence concerns the gene IDO1 and neoplasm.